SYN-TECH Chemical & Pharmaceutical Co. Ltd.

As of June 30, 2026, SYN-TECH Chemical & Pharmaceutical Co. Ltd. carries a market capitalization of 3.17B, placing it among publicly traded companies globally. Its enterprise value stands at 2.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

SYN-TECH Chemical & Pharmaceutical Co. Ltd.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, SYN-TECH Chemical & Pharmaceutical Co. Ltd. has 44.59M shares outstanding.

As of June 30, 2026, SYN-TECH Chemical & Pharmaceutical Co. Ltd. trades at a trailing price-to-earnings ratio of 11.75. The price-to-sales ratio is 2.52, and the price-to-book ratio stands at 1.23.

As of June 30, 2026, SYN-TECH Chemical & Pharmaceutical Co. Ltd. trades at an EV/EBITDA multiple of 4.77 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 6.81 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. SYN-TECH Chemical & Pharmaceutical Co. Ltd. trades at an EV/FCF ratio of 5.90, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.32B versus a market cap of 3.17B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SYN-TECH Chemical & Pharmaceutical Co. Ltd. maintains a current ratio of 3.43, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.89, indicating elevated leverage, while an interest coverage ratio of 295.85 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SYN-TECH Chemical & Pharmaceutical Co. Ltd. posted a return on equity (ROE) of 10.88, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.75 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.94, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.21, useful for judging operating efficiency across full business cycles. The company generates approximately 5.67M in revenue per employee across its workforce of 222.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.79 indicates how many times SYN-TECH Chemical & Pharmaceutical Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SYN-TECH Chemical & Pharmaceutical Co. Ltd. recorded 76.14M in income tax expense. That works out to an effective tax rate of 21.95, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 346.86M, leaving 270.71M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, SYN-TECH Chemical & Pharmaceutical Co. Ltd.'s stock has gained approximately 0.27% over the past 52 weeks. The 50-day moving average sits at 74.73, while the 200-day moving average is 72.76.

Over the twelve months ended June 30, 2026, SYN-TECH Chemical & Pharmaceutical Co. Ltd. generated 1.26B in revenue and converted that into 270.71M in net income, yielding earnings per share of 6.05. EBITDA reached 485.79M, while operating income came in at 339.97M.

As of June 30, 2026, SYN-TECH Chemical & Pharmaceutical Co. Ltd. holds 1.11B in cash and equivalents against 254.95M in total debt, resulting in a net debt position of -909.23M. Total book value stands at 2.58B, with working capital of 1.27B providing operational flexibility.

SYN-TECH Chemical & Pharmaceutical Co. Ltd. produced 453.91M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -62.63M in capital expenditures, free cash flow totaled 391.28M - equivalent to 8.76 per share.

Over the twelve months ended June 30, 2026, SYN-TECH Chemical & Pharmaceutical Co. Ltd. posted a gross margin of 37.81, reflecting its pricing power and cost economics. The operating margin of 26.99 and net profit margin of 21.49 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, SYN-TECH Chemical & Pharmaceutical Co. Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 12.29, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -4.00, meaning SYN-TECH Chemical & Pharmaceutical Co. Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

SYN-TECH Chemical & Pharmaceutical Co. Ltd.'s most recent stock split took place on November 16, 2021 with a 144:149 split ratio.

As of June 30, 2026, SYN-TECH Chemical & Pharmaceutical Co. Ltd. has an Altman Z-Score of 4.85, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.